Seat­tle Chil­dren's col­lab­o­ra­tion to dive in­to cell ther­a­py man­u­fac­tur­ing; Af­ter suc­cess in court, Te­va found guilty in NY

A cell and gene ther­a­py com­pa­ny is ex­tend­ing its col­lab­o­ra­tion with Seat­tle Chil­dren’s Hos­pi­tal to es­tab­lish man­u­fac­tur­ing prac­tices for cell ther­a­py, the com­pa­ny an­nounced Tues­day.

Bi­o­Life’s new lentivi­ral vec­tor man­u­fac­tur­ing site, dubbed Vec­tor­Works, will be used to find best prac­tices in bio­p­reser­va­tion and closed-sys­tem man­u­fac­tur­ing with the in­tro­duc­tion and in­te­gra­tion of Sex­ton’s AF-500. Seat­tle Chil­dren’s, and its sub­sidiary Seat­tle Chil­dren’s Ther­a­peu­tics, have used Bi­o­Life’s CryoStar for freez­ing me­dia for sev­er­al years in clin­i­cal ap­pli­ca­tions and tri­als to im­prove the post-thaw vi­a­bil­i­ty and re­cov­ery of cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER